By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
As disruptive as the COVID-19 pandemic has been to nearly everything in our world, including the U.S. stock market, which has experienced a year of record volatility, it hasn’t seemed to negatively faze investment in biopharma. In fact, as of this writing in early October, the number of biopharmaceutical company IPOs for 2020 had already surpassed the total number of biopharma IPOs for all of 2019. But the world of biopharmaceutical finance involves much more than what is being witnessed in the markets. So, we invited 10 biopharmaceutical industry finance experts to provide their perspectives on everything from remote work, to supply chains, to the reshoring of U.S. biopharmaceutical manufacturing operations and more during this unprecedented year, along with what to expect for 2021 and beyond.